CD3-specific antibody-induced active tolerance: from bench to bedside (original) (raw)

• Kung, P., Goldstein, G., Reinherz, E. L. & Schlossman, S. F. Monoclonal antibodies defining distinctive human T-cell surface antigens. Science 206, 347–349 (1979).
  Article CAS PubMed Google Scholar
• Cosimi, A. B. et al. Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N. Engl. J. Med. 305, 308–314 (1981). The first pilot clinical trial to indicate that OKT3 can reverse ongoing renal-allograft rejection.
  Article CAS PubMed Google Scholar
• Cosimi, A. B. et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 32, 535–539 (1981).
  Article CAS PubMed Google Scholar
• Clevers, H., Alarcon, B., Wileman, T. & Terhorst, C. The T-cell receptor/CD3 complex: a dynamic protein ensemble. Annu. Rev. Immunol. 6, 629–662 (1988).
  Article CAS PubMed Google Scholar
• Davis, M. M. & Chien, Y. H. in Fundamental Immunology (ed. Paul, W. E.) 341–366 (Raven Press, New York, 1999).
  Google Scholar
• Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N. Engl. J. Med. 313, 337–342 (1985). The first randomized, multi-centre trial to show the clinical effectiveness of OKT3 as an immunosuppressant in renal transplantation.
• Vigeral, P. et al. Prophylactic use of OKT3 monoclonal antibody in cadaver kidney recipients. Utilization of OKT3 as the sole immunosuppressive agent. Transplantation 41, 730–733 (1986).
  Article CAS PubMed Google Scholar
• Debure, A. et al. One-month prophylactic use of OKT3 in cadaver kidney transplant recipients. Transplantation 45, 546–553 (1988).
  Article CAS PubMed Google Scholar
• Frey, D. J. et al. Sequential therapy — a prospective randomized trial of MALG versus OKT3 for prophylactic immunosuppression in cadaver renal allograft recipients. Transplantation 54, 50–56 (1992).
  Article CAS PubMed Google Scholar
• Abramowicz, D. et al. The long-term effects of prophylactic OKT3 monoclonal antibody in cadaver kidney transplantation — a single-center, prospective, randomized study. Transplantation 54, 433–437 (1992).
  Article CAS PubMed Google Scholar
• Woodle, E. S. et al. OKT3 therapy for hepatic allograft rejection. Differential response in adults and children. Transplantation 51, 1207–1212 (1991).
  Article CAS PubMed Google Scholar
• Gilbert, E. M. et al. Treatment of refractory cardiac allograft rejection with OKT3 monoclonal antibody. Am. J. Med. 82, 202–206 (1987).
  Article CAS PubMed Google Scholar
• Farges, O. et al. A randomized trial of OKT3-based versus cyclosporine-based immunoprophylaxis after liver transplantation. Long-term results of a European and Australian multicenter study. Transplantation 58, 891–898 (1994).
  Article CAS PubMed Google Scholar
• Millis, J. M. et al. Randomized prospective trial of OKT3 for early prophylaxis of rejection after liver transplantation. Transplantation 47, 82–88 (1989).
  Article CAS PubMed Google Scholar
• Robbins, R. C., Oyer, P. E., Stinson, E. B. & Starnes, V. A. The use of monoclonal antibodies after heart transplantation. Transplant. Sci. 2, 22–27 (1992).
  Google Scholar
• Deeb, G. M. et al. A randomized prospective comparison of MALG with OKT3 for rescue therapy of acute myocardial rejection. Transplantation 51, 180–183 (1991).
  Article CAS PubMed Google Scholar
• Goldstein, G., Kremer, A. B., Barnes, L. & Hirsch, R. L. OKT3 monoclonal antibody reversal of renal and hepatic rejection in pediatric patients. J. Pediatr. 111, 1046–1050 (1987).
  Article CAS PubMed Google Scholar
• Niaudet, P., Jean, G., Broyer, M. & Chatenoud, L. Anti-OKT3 response following prophylactic treatment in paediatric kidney transplant recipients. Pediatr. Nephrol. 7, 263–267 (1993).
  Article CAS PubMed Google Scholar
• Leone, M. R. et al. Monoclonal antibody OKT3 therapy in pediatric kidney transplant recipients. J. Pediatr. 116, S86–S91 (1990).
  Article CAS PubMed Google Scholar
• Broyer, M. et al. Prophylactic OKT3 monoclonal antibody versus antilymphocyte globulins: a prospective, randomized study in 148 first cadaver kidney grafts. Transplant. Proc. 25, 570–571 (1993).
  CAS PubMed Google Scholar
• Chatenoud, L. et al. Human in vivo antigenic modulation induced by the anti-T-cell OKT3 monoclonal antibody. Eur. J. Immunol. 12, 979–982 (1982). The first demonstration that T-cell receptor down-modulation is an important mode of action of OKT3.
  Article CAS PubMed Google Scholar
• Chatenoud, L. et al. Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. J. Immunol. 137, 830–838 (1986). The first detailed analysis of the fine specificity of the humoral response that is elicited in patients after injection of OKT3. Human antibodies are directed exclusively against isotypic and idiotypic determinants of the xenogeneic antibody molecule. Only idiotype-specific antibodies are neutralizing.
  CAS PubMed Google Scholar
• Leo, O., Foo, M., Sachs, D. H., Samelson, L. E. & Bluestone, J. A. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc. Natl Acad. Sci. USA 84, 1374–1378 (1987).
  Article CAS PubMed PubMed Central Google Scholar
• Hirsch, R., Eckhaus, M., Auchincloss, H. Jr, Sachs, D. H. & Bluestone, J. A. Effects of in vivo administration of anti-T3 monoclonal antibody on T-cell function in mice. I. Immunosuppression of transplantation responses. J. Immunol. 140, 3766–3772 (1988).
  CAS PubMed Google Scholar
• Johnson, B. D., McCabe, C., Hanke, C. A. & Truitt, R. L. Use of anti-CD3ε F(ab')2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone-marrow transplantation. J. Immunol. 154, 5542–5554 (1995).
  CAS PubMed Google Scholar
• Hughes, C., Wolos, J. A., Giannini, E. H. & Hirsch, R. Induction of T-helper cell hyporesponsiveness in an experimental model of autoimmunity by using nonmitogenic anti-CD3 monoclonal antibody. J. Immunol. 153, 3319–3325 (1994).
  CAS PubMed Google Scholar
• Herold, K. C. et al. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes 41, 385–391 (1992).
  Article CAS PubMed Google Scholar
• Chatenoud, L., Thervet, E., Primo, J. & Bach, J. F. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc. Natl Acad. Sci. USA 91, 123–127 (1994). The first report to show that a short treatment with CD3-specific antibodies restores self-tolerance, thereby inducing stable remission of established diabetes in non-obese diabetic (NOD) mice.
  Article CAS PubMed PubMed Central Google Scholar
• Nooij, F. J. & Jonker, M. The effect on skin allograft survival of a monoclonal antibody specific for a polymorphic CD3-like cell-surface molecule in rhesus monkeys. Eur. J. Immunol. 17, 1089–1093 (1987).
  Article CAS PubMed Google Scholar
• Plain, K. M., Chen, J., Merten, S., He, X. Y. & Hall, B. M. Induction of specific tolerance to allografts in rats by therapy with non-mitogenic, non-depleting anti-CD3 monoclonal antibody: association with TH2 cytokines not anergy. Transplantation 67, 605–613 (1999).
  Article CAS PubMed Google Scholar
• Chatenoud, L., Primo, J. & Bach, J. F. CD3 antibody-induced dominant self-tolerance in overtly diabetic NOD mice. J. Immunol. 158, 2947–2954 (1997).
  CAS PubMed Google Scholar
• Hirsch, R., Archibald, J. & Gress, R. E. Differential T-cell hyporesponsiveness induced by in vivo administration of intact or F(ab')2 fragments of anti-CD3 monoclonal antibody. F(ab')2 fragments induce a selective T-helper dysfunction. J. Immunol. 147, 2088–2093 (1991).
  CAS PubMed Google Scholar
• Isaacs, J. D., Clark, M. R., Greenwood, J. & Waldmann, H. Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential. J. Immunol. 148, 3062–3071 (1992).
  CAS PubMed Google Scholar
• Wong, J. T. & Colvin, R. B. Selective reduction and proliferation of the CD4+ and CD8+ T-cell subsets with bispecific monoclonal antibodies: evidence for inter-T-cell-mediated cytolysis. Clin. Immunol. Immunopathol. 58, 236–250 (1991).
  Article CAS PubMed Google Scholar
• Jung, G., Martin, D. E. & Muller Eberhard, H. J. Induction of cytotoxicity in human peripheral-blood mononuclear cells by monoclonal antibody OKT3. J. Immunol. 139, 639–644 (1987).
  CAS PubMed Google Scholar
• Spits, H., Yssel, H., Leeuwenberg, J. & de Vries, J. E. Antigen-specific cytotoxic T-cell and antigen-specific proliferating T-cell clones can be induced to cytolytic activity by monoclonal antibodies against T3. Eur. J. Immunol. 15, 88–91 (1985).
  Article CAS PubMed Google Scholar
• Wesselborg, S., Janssen, O. & Kabelitz, D. Induction of activation-driven death (apoptosis) in activated but not resting peripheral-blood T cells. J. Immunol. 150, 4338–4345 (1993).
  CAS PubMed Google Scholar
• Janssen, O., Wesselborg, S. & Kabelitz, D. Immunosuppression by OKT3 — induction of programmed cell death (apoptosis) as a possible mechanism of action. Transplantation 53, 233–234 (1992).
  CAS PubMed Google Scholar
• Carpenter, P. A. et al. Non-Fc-receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells. J. Immunol. 165, 6205–6213 (2000).
  Article CAS PubMed Google Scholar
• Chatenoud, L. & Bach, J. F. Antigenic modulation: a major mechanism of antibody action. Immunol. Today 5, 20–25 (1984).
  Article CAS PubMed Google Scholar
• Caillat-Zucman, S. et al. The OKT3 immunosuppressive effect. In situ antigenic modulation of human graft-infiltrating T cells. Transplantation 49, 156–160 (1990).
  Article CAS PubMed Google Scholar
• Woodle, E. S. et al. Phase I trial of a humanized, Fc-receptor nonbinding OKT3 antibody, huOKT3γ1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 68, 608–616 (1999).
  Article CAS PubMed Google Scholar
• Friend, P. J. et al. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation 68, 1632–1637 (1999). References 42 and 43 describe pilot studies in renal-allograft recipients to test the safety of the two engineered, humanized, non-mitogenic CD3-specific monoclonal antibodies that are available at present for clinical use.
  Article CAS PubMed Google Scholar
• Hirsch, R., Gress, R. E., Pluznik, D. H., Eckhaus, M. & Bluestone, J. A. Effects of in vivo administration of anti-CD3 monoclonal antibody on T-cell function in mice. II. In vivo activation of T cells. J. Immunol. 142, 737–743 (1989).
  CAS PubMed Google Scholar
• Abbs, I. C. et al. Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with diminished release of pro-inflammatory cytokines. Ther. Immunol. 1, 325–331 (1994).
  CAS PubMed Google Scholar
• Routledge, E. G., Lloyd, I., Gorman, S. D., Clark, M. & Waldmann, H. A humanized monovalent CD3 antibody which can activate homologous complement. Eur. J. Immunol. 21, 2717–2725 (1991).
  Article CAS PubMed Google Scholar
• Goldstein, G. Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation. Transplant. Proc. 19, 1–6 (1987).
  CAS PubMed Google Scholar
• Abramowicz, D., Crusiaux, A. & Goldman, M. Anaphylactic shock after retreatment with OKT3 monoclonal antibody. N. Engl. J. Med. 327, 736 (1992).
  Article CAS PubMed Google Scholar
• Baudrihaye, M. F., Chatenoud, L., Kreis, H., Goldstein, G. & Bach, J. F. Unusually restricted anti-isotype human immune response to OKT3 monoclonal antibody. Eur. J. Immunol. 14, 686–691 (1984).
  Article CAS PubMed Google Scholar
• Jonker, M. & Den Brok, J. H. Idiotype switching of CD4-specific monoclonal antibodies can prolong the therapeutic effectiveness in spite of host anti-mouse IgG antibodies. Eur. J. Immunol. 17, 1547–1553 (1987).
  Article CAS PubMed Google Scholar
• Chatenoud, L., Jonker, M., Villemain, F., Goldstein, G. & Bach, J. F. The human immune response to the OKT3 monoclonal antibody is oligoclonal. Science 232, 1406–1408 (1986). The first demonstration of the oligoclonality of the human (and monkey) immune response to xenogeneic T-cell-specific monoclonal antibodies in general, and to OKT3 in particular.
  Article CAS PubMed Google Scholar
• Hricik, D. E., Mayes, J. T. & Schulak, J. A. Inhibition of anti-OKT3 antibody generation by cyclosporine — results of a prospective randomized trial. Transplantation 50, 237–240 (1990).
  Article CAS PubMed Google Scholar
• Lazarovits, A. I. et al. Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection. J. Immunol. 150, 5163–5174 (1993).
  CAS PubMed Google Scholar
• Vincenti, F. et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N. Engl. J. Med. 338, 161–165 (1998).
  Article CAS PubMed Google Scholar
• Nashan, B. et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 350, 1193–1198 (1997).
  Article CAS PubMed Google Scholar
• Maini, R. N. et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor-α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41, 1552–1563 (1998).
  Article CAS PubMed Google Scholar
• Herold, K. C. et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346, 1692–1698 (2002). The first report of a pilot clinical study using a humanized, non-mitogenic CD3-specific antibody in overt autoimmunity (insulin-dependent diabetes mellitus).
  Article CAS PubMed Google Scholar
• Utset, T. O. et al. Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J. Rheumatol. 29, 1907–1913 (2002).
  CAS PubMed Google Scholar
• Elliott, M. J. et al. Repeated therapy with monoclonal antibody to tumour-necrosis factor-α (cA2) in patients with rheumatoid arthritis. Lancet 344, 1125–1127 (1994).
  Article CAS PubMed Google Scholar
• Routledge, E. G., Falconer, M. E., Pope, H., Lloyd, I. S. & Waldmann, H. The effect of aglycosylation on the immunogenicity of a humanized therapeutic CD3 monoclonal antibody. Transplantation 60, 847–853 (1995).
  Article CAS PubMed Google Scholar
• Alegre, M. L. et al. An anti-murine CD3 monoclonal antibody with a low affinity for Fcγ receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity. J. Immunol. 155, 1544–1555 (1995).
  CAS PubMed Google Scholar
• Van Wauwe, J. P., de Mey, J. R. & Goossens, J. G. OKT3: a monoclonal anti-human T-lymphocyte antibody with potent mitogenic properties. J. Immunol. 124, 2708–2713 (1980).
  CAS PubMed Google Scholar
• Van Lier, R. A., Boot, J. H., de Groot, E. R. & Aarden, L. A. Induction of T-cell proliferation with anti-CD3 switch-variant monoclonal antibodies: effects of heavy chain isotype in monocyte-dependent systems. Eur. J. Immunol. 17, 1599–1604 (1987).
  Article CAS PubMed Google Scholar
• Chatenoud, L. et al. Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor-necrosis factor and interferon-γ. N. Engl. J. Med. 320, 1420–1421 (1989).
  Article CAS PubMed Google Scholar
• Abramowicz, D. et al. Release of tumor-necrosis factor, interleukin-2, and γ-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 47, 606–608 (1989).
  Article CAS PubMed Google Scholar
• Ferran, C. et al. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T-cell activation. Eur. J. Immunol. 20, 509–515 (1990).
  Article CAS PubMed Google Scholar
• Alegre, M. et al. Hypothermia and hypoglycemia induced by anti-CD3 monoclonal antibody in mice: role of tumor-necrosis factor. Eur. J. Immunol. 20, 707–710 (1990).
  Article CAS PubMed Google Scholar
• Ferran, C. et al. Anti-tumor-necrosis factor modulates anti-CD3-triggered T-cell cytokine gene expression in vivo. J. Clin. Invest. 93, 2189–2196 (1994).
  Article CAS PubMed PubMed Central Google Scholar
• Durez, P. et al. In vivo induction of interleukin-10 by anti-CD3 monoclonal antibody or bacterial lipopolysaccharide: differential modulation by cyclosporin A. J. Exp. Med. 177, 551–555 (1993).
  Article CAS PubMed Google Scholar
• Yoshimoto, T. & Paul, W. E. CD4pos, NK1.1pos T cells promptly produce interleukin-4 in response to in vivo challenge with anti-CD3. J. Exp. Med. 179, 1285–1295 (1994).
  Article CAS PubMed Google Scholar
• Ferran, C. et al. Inter-mouse strain differences in the in vivo anti-CD3-induced cytokine release. Clin. Exp. Immunol. 86, 537–543 (1991).
  Article CAS PubMed PubMed Central Google Scholar
• Ferran, C. et al. Cascade modulation by anti-tumor necrosis factor monoclonal antibody of interferon-γ, interleukin-3 and interleukin-6 release after triggering of the CD3/T-cell receptor activation pathway. Eur. J. Immunol. 21, 2349–2353 (1991).
  Article CAS PubMed Google Scholar
• Chatenoud, L., Legendre, C., Kurrle, R., Kreis, H. & Bach, J. F. Absence of clinical symptoms following the first injection of anti-T-cell receptor monoclonal antibody (BMA 031) despite isolated TNF release. Transplantation 55, 443–445 (1993).
  Article CAS PubMed Google Scholar
• Charpentier, B. et al. Evidence that antihuman tumor-necrosis factor monoclonal antibody prevents OKT3-induced acute syndrome. Transplantation 54, 997–1002 (1992).
  Article CAS PubMed Google Scholar
• Hirsch, R., Bluestone, J. A., de Nenno, L. & Gress, R. E. Anti-CD3 F(ab')2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb. Transplantation 49, 1117–1123 (1990).
  Article CAS PubMed Google Scholar
• Woodle, E. S. et al. Anti-CD3 monoclonal antibody therapy. An approach toward optimization by in vitro analysis of new anti-CD3 antibodies. Transplantation 52, 361–368 (1991).
  Article CAS PubMed Google Scholar
• Parlevliet, K. J. et al. In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants. J. Clin. Invest. 93, 2519–2525 (1994).
  Article CAS PubMed PubMed Central Google Scholar
• Bolt, S. et al. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur. J. Immunol. 23, 403–411 (1993).
  Article CAS PubMed Google Scholar
• Alegre, M. L. et al. A non-activating 'humanized' anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation 57, 1537–1543 (1994). References 78 and 79 characterize the two engineered, humanized, non-mitogenic CD3-specific monoclonal antibodies that are available at present for clinical use.
  Article CAS PubMed Google Scholar
• Chatenoud, L., Legendre, C., Ferran, C., Bach, J. F. & Kreis, H. Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome — dosage and kinetics prerequisites. Transplantation 51, 334–338 (1991).
  Article CAS PubMed Google Scholar
• Riechmann, L., Clark, M., Waldmann, H. & Winter, G. Reshaping human antibodies for therapy. Nature 332, 323–327 (1988).
  Article CAS PubMed Google Scholar
• Monaco, A. P., Wood, M. L. & Russell, P. S. Studies on heterologous antilymphocyte serum in mice. III. Immunological tolerance and chimerism produced across the H2-locus with adult thymectomy and antilymphocyte serum. Ann. NY Acad. Sci. 129, 190–209 (1966).
  Article Google Scholar
• Wood, M. L., Monaco, A. P., Gozzo, J. J. & Liegeois, A. Use of homozygous allogeneic bone marrow for induction of tolerance with antilymphocyte serum: dose and timing. Transplant. Proc. 3, 676–679 (1971).
  CAS PubMed Google Scholar
• Benjamin, R. J. & Waldmann, H. Induction of tolerance by monoclonal antibody therapy. Nature 320, 449–451 (1986).
  Article CAS PubMed Google Scholar
• Gutstein, N. L., Seaman, W. E., Scott, J. H. & Wofsy, D. Induction of immune tolerance by administration of monoclonal antibody to L3T4. J. Immunol. 137, 1127–1132 (1986).
  CAS PubMed Google Scholar
• Pearson, T. C., Madsen, J. C., Larsen, C. P., Morris, P. J. & Wood, K. J. Induction of transplantation tolerance in adults using donor antigen and anti-CD4 monoclonal antibody. Transplantation 54, 475–483 (1992).
  Article CAS PubMed Google Scholar
• Shizuru, J. A., Taylor-Edwards, C., Banks, B. A., Gregory, A. K. & Fathman, C. G. Immunotherapy of the nonobese diabetic mouse: treatment with an antibody to T-helper lymphocytes. Science 240, 659–662 (1988).
  Article CAS PubMed Google Scholar
• Qin, S. X., Cobbold, S., Benjamin, R. & Waldmann, H. Induction of classical transplantation tolerance in the adult. J. Exp. Med. 169, 779–794 (1989).
  Article CAS PubMed Google Scholar
• Qin, S. et al. 'Infectious' transplantation tolerance. Science 259, 974–977 (1993).
  Article CAS PubMed Google Scholar
• Larsen, C. P. et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381, 434–438 (1996).
  Article CAS PubMed Google Scholar
• Lenschow, D. J. et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science 257, 789–792 (1992).
  Article CAS PubMed Google Scholar
• Lakkis, F. G. et al. Blocking the CD28–B7 T-cell costimulation pathway induces long-term cardiac allograft acceptance in the absence of IL-4. J. Immunol. 158, 2443–2448 (1997).
  CAS PubMed Google Scholar
• Kirk, A. D. et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nature Med. 5, 686–693 (1999).
  Article CAS PubMed Google Scholar
• Nicolls, M. R. et al. Induction of long-term specific tolerance to allografts in rats by therapy with an anti-CD3-like monoclonal antibody. Transplantation 55, 459–468 (1993). The first demonstration of the tolerogenic properties of CD3-specific antibodies in a cardiac-allograft rat transplant model.
  Article CAS PubMed Google Scholar
• Smith, J. A., Tang, Q. & Bluestone, J. A. Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual TH subsets. J. Immunol. 160, 4841–4849 (1998).
  CAS PubMed Google Scholar
• Oldstone, M. B., Nerenberg, M., Southern, P., Price, J. & Lewicki, H. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell 65, 319–331 (1991).
  Article CAS PubMed Google Scholar
• Von Herrath, M. G., Dockter, J. & Oldstone, M. B. How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model. Immunity 1, 231–242 (1994).
  Article CAS PubMed Google Scholar
• Ohashi, P. S. et al. Ablation of 'tolerance' and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 65, 305–317 (1991).
  Article CAS PubMed Google Scholar
• Seewaldt, S. et al. Virus-induced autoimmune diabetes: most β-cells die through inflammatory cytokines and not perforin from autoreactive (anti-viral) cytotoxic T-lymphocytes. Diabetes 49, 1801–1809 (2000).
  Article CAS PubMed Google Scholar
• Von Herrath, M. G., Coon, B., Wolfe, T. & Chatenoud, L. Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter–lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance. J. Immunol. 168, 933–941 (2002).
  Article CAS PubMed Google Scholar
• Askenase, P. W., Hayden, B. J. & Gershon, R. K. Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses. J. Exp. Med. 141, 697–702 (1975).
  Article CAS PubMed Google Scholar
• Miyazaki, C., Nakamura, T., Kaneko, K., Mori, R. & Shibasaki, H. Reinduction of experimental allergic encephalomyelitis in convalescent Lewis rats with cyclophosphamide. J. Neurol. Sci. 67, 277–284 (1985).
  Article CAS PubMed Google Scholar
• Kardys, E. & Hashim, G. A. Experimental allergic encephalomyelitis in Lewis rats: immunoregulation of disease by a single amino-acid substitution in the disease-inducing determinant. J. Immunol. 127, 862–866 (1981).
  CAS PubMed Google Scholar
• Asano, M., Toda, M., Sakaguchi, N. & Sakaguchi, S. Autoimmune disease as a consequence of developmental abnormality of a T-cell subpopulation. J. Exp. Med. 184, 387–396 (1996).
  Article CAS PubMed Google Scholar
• Itoh, M. et al. Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J. Immunol. 162, 5317–5326 (1999).
  CAS PubMed Google Scholar
• Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. & Toda, M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155, 1151–1164 (1995).
  CAS PubMed Google Scholar
• Sakaguchi, S., Takahashi, T. & Nishizuka, Y. Study on cellular events in postthymectomy autoimmune oophoritis in mice. I. Requirement of Lyt-1 effector cells for oocytes damage after adoptive transfer. J. Exp. Med. 156, 1565–1576 (1982).
  Article CAS PubMed Google Scholar
• Suri-Payer, E., Kehn, P. J., Cheever, A. W. & Shevach, E. M. Pathogenesis of post-thymectomy autoimmune gastritis. Identification of anti-H/K adenosine triphosphatase-reactive T cells. J. Immunol. 157, 1799–1805 (1996).
  CAS PubMed Google Scholar
• Suri-Payer, E., Amar, A. Z., Thornton, A. M. & Shevach, E. M. CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J. Immunol. 160, 1212–1218 (1998).
  CAS PubMed Google Scholar
• Takahashi, T. et al. Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192, 303–310 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Salomon, B. et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12, 431–440 (2000).
  Article CAS PubMed Google Scholar
• Ludviksson, B. R., Ehrhardt, R. O. & Strober, W. TGF-β production regulates the development of the 2,4,6-trinitrophenol-conjugated keyhole limpet hemocyanin-induced colonic inflammation in IL-2-deficient mice. J. Immunol. 159, 3622–3628 (1997).
  CAS PubMed Google Scholar
• Smith, J. A., Tso, J. Y., Clark, M. R., Cole, M. S. & Bluestone, J. A. Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T-cell receptor signal and induce clonal anergy. J. Exp. Med. 185, 1413–1422 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Chau, L. A., Tso, J. Y., Melrose, J. & Madrenas, J. HuM291 (Nuvion), a humanized Fc-receptor-non-binding antibody against CD3, anergizes peripheral-blood T cells as partial agonist of T-cell receptor. Transplantation 71, 941–950 (2001).
  Article CAS PubMed Google Scholar
• Bank, I. & Chess, L. Perturbation of the T4 molecule transmits a negative signal to T cells. J. Exp. Med. 162, 1294–1303 (1985).
  Article CAS PubMed Google Scholar
• Jabado, N. et al. CD4 ligands inhibit the formation of multifunctional transduction complexes involved in T-cell activation. J. Immunol. 158, 94–103 (1997).
  CAS PubMed Google Scholar
• Jauliac, S. et al. Ligands of CD4 inhibit the association of phospholipase Cγ1 with phosphoinositide 3-kinase in T cells: regulation of this association by the phosphoinositide 3-kinase activity. Eur. J. Immunol. 28, 3183–3191 (1998).
  Article CAS PubMed Google Scholar